Members of Cytura Therapeutics Board
Members of Cytura Therapeutics Board are representatives of the contributors to the seed funding :
Thuja Capital Healthcare (Seed) Fund II, BOM Brabant Ventures, the Centre for Drug Design and Discovery (CD3) – KU Leuven and the Gemma Frisius Fund (GFF)
Harrold van Barlingen is managing partner of venture capital company Thuja Capital ManagementPrior to founding Thuja in 2006.
He headed the life science effort of AlpInvest Partners managing a portfolio of over 30 companies.Harrold joined AlpInvest Partners in 2001, from the Boston Consulting Group (BCG), where he worked as a consultant in management and strategy. Before BCG, he was acting head of the continental activities of the Lewin Group (a Quintiles subsidiary), an internationally active firm specialized in the field of health economics.
Harrold holds an MSc degree in Medical Biology and a PhD in Medicine, both from Utrecht University.
Dr. Barf is an independent pharma industry expert.
He has extensive experience in pharmaceutical Research and Development and contributed to the delivery of several clinical candidates in the metabolic disease, autoimmune and oncology space. He successfully exploited the covalent binding paradigm for kinases, resulting for instance in the discovery of BTK inhibitor acalabrutinib.
Tjeerd joined the pharmaceutical industry in 1997 and engaged in various project and line management roles at Pharmacia & Upjohn, Biovitrum, Organon, Schering-Plough and MSD. He co-founded Acerta Pharma BV and served as the EVP of Chemistry since its inception in 2013. He holds a PhD in Medicinal Chemistry and MSc in Organic Chemistry from the University of Groningen, The Netherlands.
Patrick Chaltin is the Managing Director of the Centre for Drug Design and Discovery (CD3) of KU Leuven R&D, an investment fund and drug discovery centre established by KU Leuven and EIF in 2006.
CD3 focuses on the discovery, development and exploitation of new innovative small molecule drugs based on excellent (academic) biomedical research. He is a qualified European Patent Attorney and was previously active as IP manager at the IP unit of KU Leuven R&D, which he joined in 2002. He is member of the Board of Directors of several biotechs and has been a member of the deal flow committee of Capricorn Venture Partners.
He studied Pharmaceutical Sciences and obtained a Ph.D. in this field at the laboratory of Medicinal Chemistry of KU Leuven (Rega Institute) after which he performed post-doc research in the field of drug discovery. Patrick is co-author of several peer-reviewed scientific publications and is inventor on multiple patent applications.
About Thuja Capital:
Thuja Capital manages several venture capital funds aimed at building and scaling companies in the fields of (bio)pharmaceuticals, medtech and digital health. Thuja aims to bring innovations to patients and society by providing capital to daring entrepreneurs with ground-breaking product concepts, addressing unmet medical needs. The investment team of Thuja consists of seasoned investors and entrepreneurs. Consistently performing in the top quartile, the team has backed and helped to build several of today’s unicorns.
For more information: www.thujacapital.com
About the Centre for Drug Design and Discovery (CD3) – KU Leuven:
The Centre for Drug Design and Discovery (CD3) is an investment fund and drug translational platform with a focus on the discovery and development of new innovative small molecules based on excellent academic biomedical research. CD3 was set up in 2006 by KU Leuven Research & Development and the European Investment Fund (EIF) and launched a 60 million euro fund in 2016. Several of its programs have been successfully partnered to Pharma or incorporated in spin-offs.
For more information: www.cd3.eu
About BOM Brabant Ventures:
The Brabant Development Agency (BOM) is a growth accelerator. With the help of its unique knowledge and capital, BOM uses the Brabant Ventures label to focus on the accelerated and future-proof growth of ambitious Brabant startups and scale-ups in the High-Tech Systems and Software, Agri-food, Life Sciences & Health, Maintenance, Supply Chain, and Bio-based Economy top industries.
For more information: www.bom.nl/brabant-ventures
Gemma Frisius Fund (GFF) is a seed capital fund, established in 1997 as a joint venture between KU Leuven, KBC Private Equity and BNP Paribas Fortis Private Equity. It combines the research and technology transfer expertise of KU Leuven (Europe’s most innovative university) with the financial and investment expertise of the two financial partners. GFF provides seed capital in the early development phases of innovative, research-based spin-off companies originating from all technology domains and provides hands-on support in their further growth process.
For more information: http://lrd.kuleuven.be/en/spinoff/gemma-frisius-fund